Email this article Practical recommendations for the prevention and correction of adverse reactions of sunitinib
- Authors: Gutorov S.L.1, Borisova E.I.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 6, No 2 (2010)
- Pages: 8-13
- Section: LECTURE
- Published: 30.06.2010
- URL: https://oncourology.abvpress.ru/oncur/article/view/41
- DOI: https://doi.org/10.17650/1726-9776-2010-6-2-8-13
- ID: 41
Cite item
Full Text
Abstract
At present Sunitinib is the drug of choice in the treatment of metastatic renal cell carcinoma. In some cases complications due to the use of the drug make it to be unreasonably discontinued, which potentially affects the results of therapy. The paper proposes practical recommendations for the prevention, timely detection, and correction of the adverse reactions of Sunitinib, which enables the treatment to be performed safely and in adequate doses.
About the authors
S. L. Gutorov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: s1gutorov@gmail.com
Russian Federation
E. I. Borisova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: s1gutorov@gmail.com
Russian Federation
References
Supplementary files
